Esperion Therapeutics (ESPR) EBIT Growth (3y) (2015 - 2026)
Esperion Therapeutics (ESPR) EBIT Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 273.62% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 3.84% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -59.82% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 4.63% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -30.05% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 54.58% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 40.17% |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | 48.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.65% |
| Dec 31, 2025 | 58.80% |
| Sep 30, 2025 | 37.92% |
| Jun 30, 2025 | 28.77% |
| Mar 31, 2025 | 19.90% |
| Dec 31, 2024 | 57.01% |
| Sep 30, 2024 | 34.00% |
| Jun 30, 2024 | 27.64% |
| Mar 31, 2024 | 42.15% |
| Dec 31, 2023 | 23.75% |
| Sep 30, 2023 | 30.08% |
| Jun 30, 2023 | -31.75% |
| Mar 31, 2023 | 13.25% |
| Dec 31, 2022 | 10.33% |
| Sep 30, 2022 | 14.14% |
| Jun 30, 2022 | 1.79% |
| Mar 31, 2022 | -35.62% |
| Dec 31, 2021 | 2.84% |
| Sep 30, 2021 | -3.31% |
| Jun 30, 2021 | 11.21% |